There have been controversies about CD34 and CD38 expression by human cord blood (CB) stem cells. Using the newborn NOD/SCID/b2-microglobulin-null mouse assay that we recently developed, we examined the in vivo engrafting capability of human CB cells. Almost all of the 4-5 months engrafting cells were found in CD34 + population. 
Introduction
During the last decade, expression of the CD34 antigen has been used to define both human and murine hematopoietic stem cells. Even though the majority of adult mouse stem cells are CD34 À , 1,2 stem cells in the newborn and juvenile mice express CD34 until the mice reach maturity 3 at the age of 7-10 weeks. Experiments using umbilical cord blood (CB) to identify human stem cells have produced varied results. Several groups have reported the presence of candidate stem cells in the CD34
À population of CB cells. Bhatia et al 4 reported that 34 À Lin À CB cells contain SCID-repopulating activity. Nakamura et al 5 and Ando et al 6 cultured 34 À CB cells for 7 days and observed SCID-repopulating capability in the 34 + cells that formed in the culture. Conversely, both Verstegen et al 7 and Gao et al 8 detected only low-level chimeras when 34 À CB cells were transplanted into NOD/SCID mice. While there may be several reasons for these discordant results, one possibility is the assay system. Both the sensitivity of the assay and the timing when the engrafted cells are analyzed may be critical factors. We have recently developed an assay system 9 that involves transplantation of cells into 'conditioned' newborn mice. This allows the observation period of engraftment to be extended to 4-5 months. Additionally, we used NOD/SCID/b2-microglobulin-null (NOD/SCID/BMG null ) mice, 9 which support higher levels of xenogeneic engraftment than other conventional immune incompetent recipients. 10, 11 Using this assay, the 34 + and 34 À populations of CB cells were analyzed at 4-5 months post-transplantation. Secondary transplantation was carried out to confirm the self-renewal capability of the engrafted cells. Furthermore, we analyzed CD38 expression of the long-term repopulating cells. Our results indicated that CD34 + CD38 À cell fraction contains the majority of long-term engrafting cells. 
Materials and methods

Cell preparation
Transplantation
NOD/SCID/BMG null mice were purchased from Jackson laboratory (Bar Harbor, ME, USA), and have been bred and maintained in ventilated cages with irradiated food and sterilized water. All animal experiments were performed according to the guidelines established by the Institutional Animal Care and Use Committee of the Department of Veterans Affairs Medical Center. Newborn NOD/SCID/BMG null mice were conditioned with 37 mg/kg of 5-fluorouracil (5 FU, 50 mg/ml, Pharmacia & Upjohn, Kalamazoo, MI, USA) and 30 mg/kg of blocking anti-mouse c-kit antibody, Ack-2, as described previously. 9 Isolated human CB cells were injected through the facial vein of newborn mice 24 h after the conditioning.
Measurement of engraftment levels
At 6 weeks and 4-5 months after transplantation the mice were anesthetized by isoflurane and peripheral blood was harvested from retro-orbital plexus using heparin-coated micropipettes (Drummond Scientific Co, Broomall, PA, USA). When the mice were killed at 4-5 months post-transplantation, peripheral blood, spleen, and bone marrow were harvested. Spleens were minced between two slide glasses, made into single cell suspension with repeated passages through 25-gauge needles and filtered through 40 mm mesh. Both peripheral blood and spleen cells were incubated with 0.15 mol/l NH 4 Cl for 10 min at 371C for lysis of red blood cells. Bone marrow cells were flushed from the femurs and tibias using 25-gauge needles (Becton Dickinson and Company), and made into single cell suspension with repeated passages through 25-gauge needles. Samples were then stained with FITC-conjugated anti-human CD45 and PE-conjugated anti-human CD34, CD33, CD19 or CD3, and analyzed for the presence of human cells using a FACSCalibur (Becton Dickinson).
Secondary transplantation
At 4-5 months post-transplantation, human CD45 + cells were isolated from the bone marrow cells of primary recipient mice using anti-human CD45 microbeads (Miltenyi Biotec). All human CD45 + cells harvested from one primary recipient mouse were injected into one secondary recipient mouse. The bone marrow cells harvested from the secondary recipients were analyzed for the presence of human CD45 + and CD34 + cells 2 months after the secondary transplantation.
Results
Engraftment capability of CD34
+ cells and CD34 À cells
We have reported previously that all neonatal murine hematopoietic stem cells are CD34 + ; 3 yet some papers [4] [5] [6] suggested the existence of CD34 À stem cells in human CB. To elucidate this controversy, we examined long-term reconstituting capability of human CB CD34 + and CD34 -cells by using our newly developed assay. 9 After CB MNCs were depleted of T cells, the samples were separated into two populations based on the expression of CD34 with the use of Miltenyi microbeads. The purity of CD34 + cells was higher than 99.9% and that of CD34 À population higher than 95% (Figure 1 ). Reflecting the ratio of CD34 À cells to CD34 + , 5Â 10 6 -8 Â 10 6 CD34 À cells or 8 Â 10 4 -1.5 Â 10 5 CD34 + cells were transplanted into each recipient mouse. Recipient mice were analyzed for engraftment at 4-5 months post-transplantation. 9 The mice transplanted with CD34 À cells showed less than 1% or no human cells (Figure 2 ). In contrast, the mice transplanted with CD34 + cells showed engraftment at the levels of 27.7718.6% (Figure 2 ). All mice transplanted with CD34 + cells showed multilineage engraftment (Table 1) .
Multilineage engraftment in the bone marrow, peripheral blood, and spleen
We also analyzed bone marrow, spleen, and peripheral blood cells from four recipient mice for the levels of engraftment and lineage expressions by human cells at 4-5 months posttransplantation. Multilineage engraftment seen in a representative mouse is presented in Figure 3 . Human cells, particularly CD34 + cells and B cells, were present in all samples. The percentages of CD34 + cells were highest in the bone marrow in all of the recipients tested.
Time course of the number of human cells in peripheral blood
Since human cells were present in the peripheral blood, we compared engraftment levels of human CD45
+ cells and human (Figure 4 ). In mice of the CD34 À group, three out of four mice showed higher than 0.1% of engraftment at 2 months. At 4 months, however, human cells were absent in two out of the three positive mice. The possibility that this low level of engraftment is caused by contaminating CD34 + cells should be considered.
Secondary transplantation
To examine longer-term reconstituting capability, we carried out secondary transplantation of the human CD45 + cells recovered from primary recipient mice at 4-5 months post-transplantation. From each recipient mouse transplanted with CD34 + cells, 0.6 Â 10 6 -2 Â 10 6 human CD45 + cells were harvested. The samples were then transplanted into each secondary recipient mouse. After 2 months, the secondary recipients were analyzed for the presence of human cells. All secondary recipient mice transplanted with CD34 + cells showed multilineage engraftment (Table 2 ). Figure 5 presents cytograms seen in a representative secondary recipient. Since the levels of engraftment in the primary recipients of CD34 À cells were very low (Figure 2 ), we tested only the marrow cells showing higher than 0.1% of human CD45 + cells. In one experiment, we pooled marrow cells from five recipients. None of the six secondary recipients, including the one transplanted with pooled bone marrow cells, showed detectable levels of secondary engraftment. These observations extend the results presented in Figure 2 and Table 1 of primary transplantation, and strongly indicate that 
Expression of CD38
In the final series of experiments, we examined CD38 expression. Since long-term engrafting cells with secondary reconstitution capability proved to express CD34, we studied the expression of CD38 by CD34 + cells. CD34 + CB cells isolated with immunomagnetic beads were stained with FITCconjugated anti-human CD38 and PE-conjugated anti-human CD34 (Figure 6 ). Reflecting the ratio of CD34 + CD38 À cells to CD34 + CD38 + cells, 2.0 Â 10 4 CD34 + CD38 À cells or 6.0 Â 10 4 CD34 + CD38 + cells were transplanted into each newborn mouse. The engraftment levels and lineage expression analyzed at 4 months post-transplantation are presented in Figure 7 and Table 3 , respectively. Clearly, the majority of long-term engrafting cells were in the CD34 + CD38 À fraction. We then examined secondary engrafting capability of the human CD45 + cells recovered from the bone marrow of primary recipients. Only the cells isolated from mice transplanted with CD34 + CD38 À cells were capable of secondary reconstitution. A representative comparison of the secondary engraftment capability of CD34 + CD38 À cells and CD34 + CD38 + cells is shown in Figure 8 . These results strongly indicated that all longterm engrafting cells in human CB are CD34 + CD38
À .
Discussion
Characterization of the surface phenotypes of hematopoietic stem cells has long been one of the major objectives in stem cell While the majority of adult stem cells are CD34 À , activation of the stem cells with cytokines such as granulocyte colonystimulating factor 13 or a combination of steel factor and interleukin-11 2 induces expression of CD34. There is also developmental control of the phenotype of murine stem cells. Stem cells express CD34 at neonatal and juvenile period and, at approximately five weeks of age, begin to lose CD34 expression. 3 In adult mice, the expression of CD38 appears to be completely reciprocal with CD34; that is, CD34 + stem cells are CD38 À and CD34 À stem cells are CD38 + . 14 The murine model predicted that human CB stem cells would be CD34 + . However, as discussed earlier, recent publications have been contradictory as to the incidence of CD34
À SCID repopulating cells in CB. [4] [5] [6] We tested this controversy by using our recently developed assay based on newborn NOD/SCID/ BMG null mice. 9 Our results indicated that CB CD34 + cells have more than 100-fold higher engraftment capability than CB CD34 À cells at 4-5 months post-transplantation. Also, secondary reconstitution capability existed exclusively in the CD34 + population. These results are in complete agreement with the studies of murine stem cells and are consistent with the previous report by Gao et al, 8 who used NOD/SCID mice and analyzed the engraftment levels at 8 weeks. We also tested the expression of CD38 by human CB stem cells. The results indicated that the CD34 + CD38
À cells are responsible for the long-term engrafment. It has been proposed that the hematopoietic stem cells in mice of all ontogenetic stages are CD38 +15 since both adult 16 and fetal 15, 16 stem cells express CD38. However, we recently observed in our laboratory that neonatal murine stem cells are CD38 À . 17 Therefore, our studies of CD38 expression by human CB stem cells are again in agreement with the studies of murine stem cells.
In conclusion, based on an assay that allows long-term observation and increased sensitivity, our characterization of the surface phenotype of newborn human stem cells is consistent with that of newborn mouse stem cells. Further analysis of the phenotype of human stem cells at different ontogenetic stages would appear to be necessary. Phenotype of human cord blood stem cells
